• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

敲低EPS8表达可减弱恩杂鲁胺耐药前列腺癌细胞的增殖。

Knockdown of EPS8 expression attenuates the proliferation of enzalutamide-resistant prostate cancer cells.

作者信息

Huang Wei-Lun, Chen Sih-Han, Wu Richard Chen-Yu, Mai Hsing-Cha, Wu Chun-Hsien, Hsieh Pei-Fang, Pang See-Tong, Lin Victor Chia-Hsiang

机构信息

Division of Urology, Department of Surgery, E-Da Hospital Kaohsiung 824, Taiwan.

Department of Nursing, I-Shou University Kaohsiung 840, Taiwan.

出版信息

Am J Cancer Res. 2024 Oct 15;14(10):4717-4730. doi: 10.62347/YQWJ7498. eCollection 2024.

DOI:10.62347/YQWJ7498
PMID:39553210
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11560819/
Abstract

Androgen deprivation therapies, the key treatment options for prostate cancer, have shown resistance and disease progression in many patients receiving these treatments. Therefore, it is crucial to identify new targetable pathways. Epidermal growth factor receptor pathway substrate 8 (Eps8) is one such potential target. Although this pathway is associated with the progression of various cancers, studies on the role of Eps8 in prostate cancer remain limited. This study investigated the role of Eps8 in prostate cancer. The LNCaP cell line and enzalutamide-resistant LNCaP (LNCaP Enz-R) cell lines were utilized for the investigation. Overexpression of Eps8 was observed in the LNCaP Enz-R cells. Transfecting pCMV-EPS8 also increased the levels of epithelial-to-mesenchymal transition (EMT), cell proliferation, and cell viability in both cell lines. Conversely, knockdown of Eps8 expression decreased the levels of EMT, cell proliferation, and cell viability in both cell lines. Furthermore, EPS8-induced EMT activation could be reversed by suppressing the Ras/JAK/PI3K signaling pathway. In vivo animal study also confirmed the crucial role of Eps8 expression in prostate cancer progression. Therefore, we suggest that targeting Eps8 by knocking down its expression is promising as a therapeutic approach for prostate cancer treatment.

摘要

雄激素剥夺疗法是前列腺癌的关键治疗选择,但在许多接受这些治疗的患者中已显示出耐药性和疾病进展。因此,确定新的可靶向通路至关重要。表皮生长因子受体通路底物8(Eps8)就是这样一个潜在靶点。尽管该通路与多种癌症的进展相关,但关于Eps8在前列腺癌中作用的研究仍然有限。本研究调查了Eps8在前列腺癌中的作用。使用LNCaP细胞系和恩杂鲁胺耐药的LNCaP(LNCaP Enz-R)细胞系进行研究。在LNCaP Enz-R细胞中观察到Eps8的过表达。转染pCMV-EPS8也增加了两种细胞系中的上皮-间质转化(EMT)水平、细胞增殖和细胞活力。相反,敲低Eps8表达降低了两种细胞系中的EMT水平、细胞增殖和细胞活力。此外,抑制Ras/JAK/PI3K信号通路可逆转EPS8诱导的EMT激活。体内动物研究也证实了Eps8表达在前列腺癌进展中的关键作用。因此,我们建议通过敲低Eps8的表达来靶向它,作为前列腺癌治疗的一种有前景的治疗方法。

相似文献

1
Knockdown of EPS8 expression attenuates the proliferation of enzalutamide-resistant prostate cancer cells.敲低EPS8表达可减弱恩杂鲁胺耐药前列腺癌细胞的增殖。
Am J Cancer Res. 2024 Oct 15;14(10):4717-4730. doi: 10.62347/YQWJ7498. eCollection 2024.
2
MYO6 contributes to tumor progression and enzalutamide resistance in castration-resistant prostate cancer by activating the focal adhesion signaling pathway.MYO6 通过激活粘着斑信号通路促进去势抵抗性前列腺癌的肿瘤进展和恩杂鲁胺耐药性。
Cell Commun Signal. 2024 Oct 24;22(1):517. doi: 10.1186/s12964-024-01897-z.
3
Combination AZD5363 with Enzalutamide Significantly Delays Enzalutamide-resistant Prostate Cancer in Preclinical Models.AZD5363 联合恩扎卢胺显著延缓临床前模型中的恩扎卢胺耐药性前列腺癌。
Eur Urol. 2015 Jun;67(6):986-990. doi: 10.1016/j.eururo.2014.08.006. Epub 2014 Aug 20.
4
Small interfering RNA targeting N-cadherin regulates cell proliferation and migration in enzalutamide-resistant prostate cancer.靶向N-钙黏蛋白的小干扰RNA调节恩杂鲁胺耐药前列腺癌中的细胞增殖和迁移。
Oncol Lett. 2022 Mar;23(3):90. doi: 10.3892/ol.2022.13210. Epub 2022 Jan 21.
5
Inhibition of protein kinase C/Twist1 signaling augments anticancer effects of androgen deprivation and enzalutamide in prostate cancer.抑制蛋白激酶 C/Twist1 信号通路增强去势和恩扎卢胺治疗前列腺癌的疗效。
Clin Cancer Res. 2014 Feb 15;20(4):951-61. doi: 10.1158/1078-0432.CCR-13-1809. Epub 2013 Dec 18.
6
Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9 to Suppress Enzalutamide-resistant Prostate Cancer Progression.使用 Malat1 小干扰 RNA 或雄激素受体剪接变体 7 降解增强剂 ASC-J9 进行临床前研究以抑制恩杂鲁胺耐药前列腺癌的进展。
Eur Urol. 2017 Nov;72(5):835-844. doi: 10.1016/j.eururo.2017.04.005. Epub 2017 May 18.
7
Inhibition of the HER2-YB1-AR axis with Lapatinib synergistically enhances Enzalutamide anti-tumor efficacy in castration resistant prostate cancer.用拉帕替尼抑制HER2-YB1-AR轴可协同增强恩杂鲁胺在去势抵抗性前列腺癌中的抗肿瘤疗效。
Oncotarget. 2015 Apr 20;6(11):9086-98. doi: 10.18632/oncotarget.3602.
8
Generation 2.5 antisense oligonucleotides targeting the androgen receptor and its splice variants suppress enzalutamide-resistant prostate cancer cell growth.针对雄激素受体及其剪接变体的 2.5 代反义寡核苷酸抑制恩杂鲁胺耐药前列腺癌细胞生长。
Clin Cancer Res. 2015 Apr 1;21(7):1675-87. doi: 10.1158/1078-0432.CCR-14-1108. Epub 2015 Jan 29.
9
Epidermal growth factor receptor kinase substrate 8 promotes the metastasis of cervical cancer via the epithelial-mesenchymal transition.表皮生长因子受体激酶底物8通过上皮-间质转化促进宫颈癌转移。
Mol Med Rep. 2016 Oct;14(4):3220-8. doi: 10.3892/mmr.2016.5638. Epub 2016 Aug 18.
10
A GATA2-CDC6 axis modulates androgen receptor blockade-induced senescence in prostate cancer.GATA2-CDC6 轴调节雄激素受体阻断诱导的前列腺癌衰老。
J Exp Clin Cancer Res. 2023 Jul 29;42(1):187. doi: 10.1186/s13046-023-02769-z.

本文引用的文献

1
Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.2022 年全球癌症统计数据:全球 185 个国家和地区 36 种癌症的发病率和死亡率全球估计数。
CA Cancer J Clin. 2024 May-Jun;74(3):229-263. doi: 10.3322/caac.21834. Epub 2024 Apr 4.
2
PTEN-PI3K pathway alterations in advanced prostate cancer and clinical implications.晚期前列腺癌中 PTEN-PI3K 通路改变及其临床意义。
Prostate. 2022 Aug;82 Suppl 1:S60-S72. doi: 10.1002/pros.24372.
3
Molecular mechanisms of neuroendocrine differentiation in prostate cancer progression.前列腺癌进展中神经内分泌分化的分子机制。
J Cancer Res Clin Oncol. 2022 Jul;148(7):1813-1823. doi: 10.1007/s00432-022-04061-7. Epub 2022 May 28.
4
Establishment of the LNCaP Cell Line - The Dawn of an Era for Prostate Cancer Research.LNCaP细胞系的建立——前列腺癌研究新时代的曙光。
Cancer Res. 2022 May 3;82(9):1689-1691. doi: 10.1158/0008-5472.CAN-22-1065.
5
Trends in Incidence of Metastatic Prostate Cancer in the US.美国转移性前列腺癌发病率的趋势。
JAMA Netw Open. 2022 Mar 1;5(3):e222246. doi: 10.1001/jamanetworkopen.2022.2246.
6
Sotorasib for Lung Cancers with p.G12C Mutation.索托拉西布治疗 p.G12C 突变型肺癌。
N Engl J Med. 2021 Jun 24;384(25):2371-2381. doi: 10.1056/NEJMoa2103695. Epub 2021 Jun 4.
7
Neuroendocrine cells of the prostate: Histology, biological functions, and molecular mechanisms.前列腺的神经内分泌细胞:组织学、生物学功能及分子机制
Precis Clin Med. 2021 Jan 28;4(1):25-34. doi: 10.1093/pcmedi/pbab003. eCollection 2021 Mar.
8
Resistance to second-generation androgen receptor antagonists in prostate cancer.前列腺癌中第二代雄激素受体拮抗剂的耐药性。
Nat Rev Urol. 2021 Apr;18(4):209-226. doi: 10.1038/s41585-021-00438-4. Epub 2021 Mar 19.
9
Effects and mechanisms of Eps8 on the biological behaviour of malignant tumours (Review).Eps8 对恶性肿瘤生物学行为的影响及其作用机制(综述)。
Oncol Rep. 2021 Mar;45(3):824-834. doi: 10.3892/or.2021.7927. Epub 2021 Jan 7.
10
Prostate Cancer Incidence and Survival, by Stage and Race/Ethnicity - United States, 2001-2017.前列腺癌发病率和存活率,按阶段和种族/族裔划分-美国,2001-2017 年。
MMWR Morb Mortal Wkly Rep. 2020 Oct 16;69(41):1473-1480. doi: 10.15585/mmwr.mm6941a1.